Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

education programme

- PMLiVE

Health equity: what will you do?

Achieving health equity is a multidimensional challenge

- PMLiVE

AstraZeneca announces positive results for Truqap in phase 3 prostate cancer study

More than 52,000 cases of prostate cancer are diagnosed in the UK every year

- PMLiVE

BeiGene’s Tevimbra approved by EC for first-line gastric and oesophageal cancer use

Gastric cancer is the fifth leading cause of cancer-related deaths globally and oesophageal cancer is the sixth

- PMLiVE

Sanofi opens €558m modular concept manufacturing facility in Singapore

The facility is designed to enable rapid changes in production capacities across medicines

- PMLiVE

How the ‘five Ps’ can close health equity gaps

Policymakers, payers, providers, patients and pharma are each uniquely able to impact health equity – and together, achieve real progress

- PMLiVE

Novartis’ Kisqali receives EC approval to treat early breast cancer patients

Approximately 70% of breast cancer cases are diagnosed in the early stages of the disease

- PMLiVE

GSK’s linerixibat shows promise in phase 3 primary biliary cholangitis trial

An estimated 510,000 people will be diagnosed with the rare liver disease globally by 2030

- PMLiVE

FDA approves Shorla Oncology’s Imkeldi to treat leukaemia and other cancers

The solution is an advanced liquid formulation of the tyrosine kinase inhibitor imatinib mesylate

- PMLiVE

All hands on deck

We all need to push harder towards environmental sustainability goals

David W. Miller

Innovating Differently: A Conversation with David W. Miller, CEO of Genesis Research Group

A recent interview with Dr. David W. Miller, Chairman and CEO of Genesis Research Group, about his vision for the business, the changing face of research, and their unique value proposition...

Genesis Research Group

- PMLiVE

Roche expands cell therapy capabilities with $1.5bn Poseida acquisition

The deal includes a BCMA-targeting allogeneic CAR-T therapy candidate for multiple myeloma

- PMLiVE

AstraZeneca announces $3.5bn US investment to boost research and manufacturing

The commitment is part of the company’s ambition to achieve $80bn in total revenue by 2030

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links